Mass spectrometry-based metabolomics in recurrent ischemic stroke: pathophysiological insights, treatment resistance, and synergistic therapies.

Recurrent ischemic stroke—when someone has a second or third stroke—remains a serious problem even when patients follow all recommended treatments like taking blood thinners, managing cholesterol, and controlling blood pressure. Scientists are now using advanced laboratory techniques called mass spectrometry-based metabolomics to understand why strokes keep happening. This technology measures hundreds of tiny chemical molecules in the body to reveal what goes wrong at the cellular level. Researchers have discovered several important metabolic disruptions that may contribute to recurrent strokes, including problems with specific fats called sphingolipids that affect blood-brain barrier health, inflammatory chemicals that promote blood clotting, energy production failures in cellular powerhouses called mitochondria, and interactions between gut bacteria byproducts and blood vessel health. Interestingly, this same metabolomics technology is also helping scientists understand why some patients don't respond well to common anti-clotting medications like clopidogrel and aspirin—their bodies process these drugs differently at the molecular level. The review also notes that metabolomics could help explain how complementary therapies like acupuncture might work biologically for stroke prevention, though this research is still in early stages. While these metabolic insights are promising for eventually creating personalized stroke prevention strategies, the technology currently faces significant challenges including standardization issues and the need for much larger patient studies before it can be used routinely in clinical practice. If considering acupuncture as part of stroke recovery or prevention, consult with a licensed acupuncturist experienced in neurological conditions.

This comprehensive review synthesizes current mass spectrometry (MS)-based metabolomics research investigating recurrent ischemic stroke pathophysiology and treatment resistance. Key metabolic disruptions identified include sphingolipid dysregulation affecting blood-brain barrier integrity, pro-inflammatory lipid mediator shifts promoting the inflammation-thrombosis axis, mitochondrial TCA cycle dysfunction, and gut microbiota-derived metabolite interactions with vascular health. The pharmacometabolomics section highlights mechanistic insights into antiplatelet therapy resistance, particularly clopidogrel bioactivation pathway variations and arachidonic acid shunting in aspirin non-responders. The review critically appraises metabolomics' potential for elucidating acupuncture's biological mechanisms in stroke prevention, while emphasizing this remains exploratory. No specific sample sizes or effect sizes are provided as this is a narrative synthesis rather than primary research. Clinical translation faces significant barriers including protocol standardization, quantification challenges, and need for large-scale validation cohorts before metabolic signatures can inform personalized risk stratification.